OFFIDANI, MASSIMO
 Distribuzione geografica
Continente #
EU - Europa 276
NA - Nord America 269
AS - Asia 194
SA - Sud America 35
AF - Africa 28
Totale 802
Nazione #
US - Stati Uniti d'America 266
IT - Italia 93
HK - Hong Kong 70
RU - Federazione Russa 54
CN - Cina 47
SG - Singapore 40
BR - Brasile 31
IE - Irlanda 20
SE - Svezia 19
DE - Germania 17
CI - Costa d'Avorio 16
UA - Ucraina 15
FR - Francia 13
GB - Regno Unito 12
TR - Turchia 11
IN - India 10
AT - Austria 9
FI - Finlandia 7
MA - Marocco 7
NL - Olanda 7
DK - Danimarca 6
JP - Giappone 6
SN - Senegal 4
KR - Corea 3
UZ - Uzbekistan 3
BE - Belgio 2
EC - Ecuador 2
MX - Messico 2
PE - Perù 2
AE - Emirati Arabi Uniti 1
BN - Brunei Darussalam 1
CA - Canada 1
HU - Ungheria 1
KZ - Kazakistan 1
LK - Sri Lanka 1
LU - Lussemburgo 1
ZA - Sudafrica 1
Totale 802
Città #
Hong Kong 69
Boardman 37
Singapore 28
Chandler 26
Dublin 20
Ashburn 18
Abidjan 16
Jacksonville 15
Fairfield 14
Moscow 13
New York 13
Wilmington 11
Los Angeles 8
São Paulo 8
The Dalles 8
Guangzhou 7
Milan 7
Rome 7
Seattle 7
Nuremberg 6
Turin 6
Woodbridge 6
Cambridge 5
Falconara Marittima 5
Houston 5
Lawrence 5
Princeton 5
Ancona 4
Bari 4
Dakar 4
Helsinki 4
Santa Clara 4
Washington 4
Ann Arbor 3
Council Bluffs 3
Pescara 3
San Mateo 3
Southwark 3
Tashkent 3
Wuxi 3
Altamura 2
Amsterdam 2
Araçatuba 2
Beijing 2
Brescia 2
Brussels 2
Centro 2
Chennai 2
Corridonia 2
Fayetteville 2
Florence 2
Foggia 2
Guayaquil 2
Guiyang 2
Jiaxing 2
Kilburn 2
Lima 2
London 2
Mexico City 2
Munich 2
Nanjing 2
Ortona 2
San Benedetto del Tronto 2
Secaucus 2
Shenzhen 2
Vasco da Gama 2
Visakhapatnam 2
Xi'an 2
Yiwu 2
Almaty 1
Ankara 1
Antakya 1
Bandar Seri Begawan 1
Bellville 1
Boston 1
Brasília 1
Brooklyn 1
Caraguatatuba 1
Casablanca 1
Chicago 1
Clifton 1
Colombo 1
Curitiba 1
Damme 1
Des Moines 1
Dubai 1
Easley 1
Eugenópolis 1
Fermo 1
Foshan 1
Governador Valadares 1
Guarujá 1
Hounslow 1
Iguatu 1
Ipatinga 1
Islington 1
Itirapina 1
Izmir 1
Jackson 1
Jinan 1
Totale 509
Nome #
Efficacy and feasibility of high-dose cytarabine plus idarubicin and amifostine as induction schedule: a prospective observational study of 100 AML elderly patients 103
Italian consensus conference for the outpatient autologous stem cell transplantation management in multiple myeloma 91
Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma 69
Real‐world assessment of treatment patterns and outcomes in patients with relapsed‐refractory multiple myeloma in an Italian haematological tertiary care centre 53
Prevalence of Type 1 Gaucher Disease in Patients with Multiple Myeloma: Updated Interim Analysis of a Prospective, Multicentre, Observational Study 50
Frequency and Risk Factors for Venous Thromboembolism Among Patients with Multiple Myeloma or Aggressive Lymphoma: A 6-Year Single Center Retrospective Analysis 49
Anticoagulation and vessel recanalization in cirrhotic patients with splanchnic vein thrombosis: A multidisciplinary “real life” experience 46
Comparison of isatuximab-pomalidomide-dexamethasone versus elotuzumab-pomalidomidedexamethasone in relapsed/refractory multiple myeloma patients: a target trial emulation using real-world data 43
Clinical Presentation, Risk Factors and Outcome of Splanchnic Venous Thrombosis: A Report on 305 Cases 37
Current Main Topics in Multiple Myeloma 36
Belantamab Mafodotin for the Treatment of Multiple Myeloma: An Overview of the Clinical Efficacy and Safety 36
Hepatic, gastric and bone marrow AL amyloidosis that began with Budd-Chiari syndrome: a case report 35
Sequential Bispecific Antibodies in Functional and Clinical High Risk Multiple Myeloma, Manifesting with Extramedullary Disease at Relapse: A Case Report 25
Prevalence of type I Gaucher disease in patients with smoldering or multiple myeloma: Results from the prospective, observational CHAGAL study 25
Novel Immunotherapies and Combinations: The Future Landscape of Multiple Myeloma Treatment 24
Belantamab Mafodotin: From Clinical Trials Data to Real-Life Experiences 22
Belantamab mafodotin in triple-refractory multiple myeloma patients: A retro-prospective observational study in Italy 21
Long-Term Survival with Multiple Myeloma: An Italian Experience 20
Long-term follow-up of cladribine treatment in hairy cell leukemia: 30-year experience in a multicentric Italian study 19
The Challenging Approach to Multiple Myeloma: From Disease Diagnosis and Monitoring to Complications Management 19
NOVELTIES ON MULTIPLE MYELOMA FROM THE MAIN 2024 HEMATOLOGY CONFERENCES 17
Efficacy and Prognostic Indicators of Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) in Daratumumab‐Refractory Multiple Myeloma Patients: A Multicenter Real‐World Study 16
Prognostic Significance of +1q Alterations in Relapsed/Refractory Multiple Myeloma Treated With Daratumumab‐, Elotuzumab‐, and Carfilzomib‐Based Triplet Regimens: A Multicenter Real‐World Analysis of 635 Patients 13
Totale 869
Categoria #
all - tutte 5.107
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 5.107


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20204 0 0 0 0 0 0 0 0 0 0 1 3
2020/202144 4 3 8 0 3 1 5 2 6 3 6 3
2021/202232 2 3 2 1 0 1 5 3 1 2 6 6
2022/202387 5 11 7 3 4 11 0 4 18 0 24 0
2023/2024182 15 5 8 11 22 18 4 5 9 7 23 55
2024/2025449 40 27 21 6 12 33 40 25 130 80 35 0
Totale 869